Clinical trials: Patients With Type 2 Diabetes
- Condition Patients With Type 2 Diabetes
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Type 2 Diabetes Mellitus
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
- Trial name
- NCT00541775
- Testing
- Sitagliptin, Comparator: Rosiglitazone, Comparator: Metformin
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prediabetes, Diabetes Type 1
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
G (guanine nucleotide binding) proteins associating with G protein-coupled receptors (GPCR) are key players in the pathogenesis of obesity and diabetes and are targets of pharmacotherapeutic inter-ventions.
- Conditions
- Prediabetes, Diabetes Type 1, Diabetes Type 2
- Trial name
- NCT02057497
- Volunteers
- healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Primary Objective: The primary objective of this study is to assess the overall safety of lixisenatide once daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in patients with type 2…
- Trial name
- NCT01940965
- Testing
- lixisenatide AVE0010, biguanide, TZD
- Where
- 27 sites in Japan
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Sanofi
PROTEINURIA, Hypertension
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
This is a study of whether valsartan affects levels of proteinuria in patients with type 2 diabetes and hypertension.
- Conditions
- PROTEINURIA, Hypertension, Type 2 Diabetes
- Trial name
- NCT00241085
- Testing
- valsartan
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.
- Trial name
- NCT01196546
- Testing
- vildagliptin/metformin
- Where
- 8 sites in Thailand
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy, Type 2 Diabetes Mellitus (T2DM)
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
The main purposes of this study are to determine: The safety of tirzepatide and any side effects that might be associated with it. How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT02759107
- Testing
- Tirzepatide, Dulaglutide
- Where
- 2 sites in United States, Singapore
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type2 Diabetes Mellitus, Chronic Kidney Disease
A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes…
- Trial name
- NCT07619157
- Testing
- ONO-3310
- Where
- Japan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients
The purpose of this phase IV clinical trial is to investigate the effect of Insulin glargine + metformin treatment vs. sulfonylurea + metformin treatment vs. DPP-4 + metformin treatment vs.
- Trial name
- NCT01206712
- Where
- Germany
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- ikfe-CRO GmbH
Type 2 Diabetes Mellitus (T2DM)
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.
- Trial name
- NCT01407003
- Testing
- LIK066
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Type II Diabetes
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
- Trial name
- NCT01619332
- Testing
- Sitagliptin, LEZ763
- Where
- 6 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
This study will investigate and compare the pharmacokinetics of a single 25-mg dose of MK-3102 in participants with moderate hepatic impairment and matched healthy participants.
- Trial name
- NCT01767688
- Testing
- MK-3102
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dietary Supplement
Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia
This is a mechanistic, single-center, double-blind, placebo- and active-controlled, three-time-period, crossover study to evaluate the effect of sprinkled format REDUCOSE compared to placebo (double-blind; confirmative) and…
- Trial name
- Stardust (NCT04877366)
- Testing
- Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
- Where
- 2 sites in United States, Singapore
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes Mellitus, Type 2, Metagenome
Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
A case-control study to identify microbiome and genetic differences between healthy people and patients with incident type 2 diabetes mellitus.
- Conditions
- Diabetes Mellitus, Type 2, Metagenome, Genetic Predisposition
- Trial name
- NCT04113239
- Testing
- 16S rRNA gene sequencing, DNA-microarray genotyping
- Where
- Russia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Atlas Biomed
Diabetes Mellitus, Type 2
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
The main purpose of this study is to determine the safety of LY2409021 in healthy participants and participants with diabetes. The study drug is given as single oral doses.
- Trial name
- NCT01606371
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Type 2 Diabetes Mellitus
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04586907
- Testing
- LY3537021
- Where
- Singapore
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8…
- Conditions
- Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
- Trial name
- NCT07807059
- Testing
- HRS-4729
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Improved Glycemic Control in Patients With Type 2 Diabetes
A Trial of HR17031 Injection With Hepatic Insufficiency
This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.
- Trial name
- NCT05151705
- Testing
- HR17031 injection
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency
The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency
The trial was designed in a single dose, open, non-randomized, multi-dose parallel control group. The study of patients were mild and moderate renal insufficiency, and matched healthy subjects.
- Trial name
- RI (NCT06883656)
- Testing
- SAL067
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Diabetes Mellitus, Type 2, Healthy
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
- Trial name
- NCT01867307
- Testing
- Empagliflozin, BI 10773
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypertension
Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes
A study comparing the antihypertensives Valsartan and Lisinporil when doses are in the morning and comparing a morning dose of Valsartan with an evening dose.
- Trial name
- NCT00241124
- Testing
- valsartan, lisinopril
- Where
- Germany
- Volunteers
- 1,099 people, healthy volunteers welcome
- Sponsor
- Novartis